Genetron Holdings Limited logo
Genetron Holdings Limited GTH

Annual report 2022
added 12-21-2024

report update icon

Genetron Holdings Limited EBITDA 2011-2025 | GTH

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Genetron Holdings Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- -518 M -268 M -307 M -233 M -134 M - - - - - -

All numbers in CNY currency

Indicator range from annual reports

Maximum Minimum Average
-134 M -518 M -292 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer EBITDA Price % 24h Market Cap Country
Brainsway Ltd. Brainsway Ltd.
BWAY
-5 M $ 17.13 1.66 % $ 99.4 M israelIsrael
Centogene N.V. Centogene N.V.
CNTG
-46 M - -6.23 % $ 30.6 M germanyGermany
DarioHealth Corp. DarioHealth Corp.
DRIO
-55.7 M $ 12.15 2.14 % $ 345 M israelIsrael
DexCom DexCom
DXCM
784 M $ 66.06 -1.34 % $ 25.5 B usaUSA
Akumin Akumin
AKU
70.1 M - -17.87 % $ 25.9 M canadaCanada
Exact Sciences Corporation Exact Sciences Corporation
EXAS
-757 M $ 101.57 0.07 % $ 18.8 B usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
-749 M $ 16.0 1.59 % $ 172 M chinaChina
Accelerate Diagnostics Accelerate Diagnostics
AXDX
-12.3 M - -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
-30.3 M - -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
-90 M $ 1.56 -3.7 % $ 1.98 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
-3.26 M - - $ 562 M britainBritain
Castle Biosciences Castle Biosciences
CSTL
24.7 M $ 38.95 0.82 % $ 1.08 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
-21.1 M - 0.22 % $ 16.8 M usaUSA
Danaher Corporation Danaher Corporation
DHR
5.58 B $ 227.29 0.42 % $ 166 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
-49 M $ 26.94 -0.74 % $ 815 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
652 M - - $ 399 M chinaChina
Mettler-Toledo International Mettler-Toledo International
MTD
50.4 M $ 1 408.65 1.08 % $ 29.9 B schweizSchweiz
Fluidigm Corporation Fluidigm Corporation
FLDM
-35.1 M - 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
-6 M - - $ 7.1 B australiaAustralia
NeoGenomics NeoGenomics
NEO
-53 M $ 12.15 2.53 % $ 1.54 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
-942 M $ 6.84 -0.36 % $ 1.48 B usaUSA
DermTech DermTech
DMTK
-104 M - -11.32 % $ 2.94 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
416 M - - $ 10.7 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
-189 M $ 19.9 -3.21 % $ 1.07 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
-323 M $ 2.12 - $ 538 M usaUSA
Celcuity Celcuity
CELC
-113 M $ 101.74 -3.33 % $ 4.01 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
-11.1 M - -8.98 % $ 14.8 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
-13.8 M $ 3.35 -6.42 % $ 107 K usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
553 M $ 26.46 -0.62 % $ 20 B niderlandNiderland
Co-Diagnostics Co-Diagnostics
CODX
-41.5 M $ 0.3 -13.39 % $ 8.8 M usaUSA
Precipio Precipio
PRPO
-6.4 M $ 24.67 -1.2 % $ 32 M usaUSA
Quidel Corporation Quidel Corporation
QDEL
1.11 B $ 28.82 0.07 % $ 1.21 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
3.32 B $ 224.13 0.84 % $ 40.6 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
301 M $ 45.14 -0.21 % $ 10 B niderlandNiderland
Guardant Health Guardant Health
GH
-401 M $ 103.55 1.45 % $ 12.7 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
-32.5 M - -6.19 % $ 10.5 M usaUSA
Sotera Health Company Sotera Health Company
SHC
382 M $ 16.76 -0.42 % $ 4.74 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
-186 M $ 49.79 -4.25 % $ 2 B usaUSA
Heska Corporation Heska Corporation
HSKA
-6.33 M - - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
-20.2 M - -20.0 % $ 1.06 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
8.49 B $ 574.27 0.46 % $ 219 B usaUSA
Illumina Illumina
ILMN
-479 M $ 134.66 -0.16 % $ 21.4 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
589 M $ 197.59 2.36 % $ 10.2 B usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
6.62 M $ 0.96 -10.6 % $ 61.9 M irlandaIrlanda
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
-111 M $ 31.39 1.47 % $ 1.88 B usaUSA
Quotient Limited Quotient Limited
QTNT
-73.9 M - -11.32 % $ 1.1 M schweizSchweiz
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
1.84 B $ 184.04 0.81 % $ 20.4 B usaUSA
Biodesix Biodesix
BDSX
-28.7 M $ 7.63 -2.8 % $ 989 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
-62.3 M $ 7.07 -2.01 % $ 641 M usaUSA